TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signaling

被引：2
|
作者：
Kato, M. [1 ]
Miyadera, K. [1 ]
Ito, K. [1 ]
Aoyagi, Y. [1 ]
Hashimoto, A. [1 ]
Yonekura, K. [1 ]
Iwasawa, Y. [1 ]
Utsugi, T. [1 ]
机构：
[1] Taiho Pharmaceut Co Ltd, Tsukuba Res Ctr, Tsukuba, Ibaraki, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70527-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
401
引用
收藏
页码：128 / 128
页数：1
相关论文
共 24 条
  • [1] In vitro characterization of TAS-121, a novel, highly potent, and mutant-specific EGFR-TKI.
    Ito, Kimihiro
    Miyadera, Kazutaka
    Aoyagi, Yoshimi
    Kato, Masanori
    Yonekura, Kazuhiko
    Iwasawa, Yoshikazu
    Utsugi, Teruhiro
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [2] Characterization of TAS-121, a novel mutant-specific EGFR-TKI, on pharmacokinetics, pharmacodynamics, and antitumor activity.
    Kato, Masanori
    Miyadera, Kazutaka
    Shibata, Yoshihiro
    Ito, Kimihiro
    Aoyagi, Yoshimi
    Chiba, Masato
    Yonekura, Kazuhiko
    Iwasawa, Yoshikazu
    Utsugi, Teruhiro
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [3] Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
    Shimamura, Takeshi
    Li, Danan
    Ji, Hongbin
    Haringsma, Henry J.
    Liniker, Elizabeth
    Borgman, Christa L.
    Lowell, April M.
    Minami, Yuko
    McNamara, Kate
    Perera, Samanthi A.
    Zaghlul, Sara
    Thomas, Roman K.
    Greulich, Heidi
    Kobayashi, Susumu
    Chirieac, Lucian R.
    Padera, Robert F.
    Kubo, Shigeto
    Takahashi, Masaya
    Tenen, Daniel G.
    Meyerson, Matthew
    Wong, Kwok-Kin
    Shapiro, Geoffrey I.
    [J]. CANCER RESEARCH, 2008, 68 (14) : 5827 - 5838
  • [4] TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
    Ito, Kimihiro
    Nishio, Makoto
    Kato, Masanori
    Murakami, Haruyasu
    Aoyagi, Yoshimi
    Ohe, Yuichiro
    Okayama, Takashige
    Hashimoto, Akihiro
    Ohsawa, Hirokazu
    Tanaka, Gotaro
    Nonoshita, Katsumasa
    Ito, Satoru
    Matsuo, Kenichi
    Miyadera, Kazutaka
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (05) : 920 - 928
  • [5] Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer
    Dong Ha Kim
    Yun Jung Choi
    Seon Ye Kim
    Jung-Eun Lee
    Ki Jung Sung
    Young Hoon Sung
    Woo Sung Kim
    Sung-Eun Kim
    Hyung Chul Ryu
    Jae Sun Kim
    Lu Guangying
    Chang-Min Choi
    Jin Kyung Rho
    Jae Cheol Lee
    [J]. Targeted Oncology, 2018, 13 : 389 - 398
  • [6] Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer
    Kim, Dong Ha
    Choi, Yun Jung
    Kim, Seon Ye
    Lee, Jung-Eun
    Sung, Ki Jung
    Sung, Young Hoon
    Kim, Woo Sung
    Kim, Sung-Eun
    Ryu, Hyung Chul
    Kim, Jae Sun
    Lu Guangying
    Choi, Chang-Min
    Rho, Jin Kyung
    Lee, Jae Cheol
    [J]. TARGETED ONCOLOGY, 2018, 13 (03) : 389 - 398
  • [7] Clinical activity and safety of the EGFR mutant-specific inhibitor, BI1482694, in patients (pts) with T790M-positive NSCLC
    Lee, J. -S.
    Park, K.
    Han, J. -Y.
    Lee, K. H.
    Kim, J. -H.
    Cho, E. K.
    Cho, J. Y.
    Min, Y. J.
    Kim, J. -S.
    Kim, H. -G.
    Kim, B. -S.
    Jung, J.
    Kim, D. -W.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 128 - 129
  • [8] Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.
    Meador, Catherine B.
    Jin, Hailing
    de Stanchina, Elisa
    Pirazzoli, Valentina
    Ladanyi, Marc
    Wang, Lu
    Chen, Xi
    Eisenberg, Rosana
    Cross, Darren
    Pao, William
    [J]. CLINICAL CANCER RESEARCH, 2014, 20
  • [9] Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
    Walter, Annette O.
    Sjin, Robert Tjin Tham
    Haringsma, Henry J.
    Ohashi, Kadoaki
    Sun, Jing
    Lee, Kwangho
    Dubrovskiy, Aleksandr
    Labenski, Matthew
    Zhu, Zhendong
    Wang, Zhigang
    Sheets, Michael
    St Martin, Thia
    Karp, Russell
    van Kalken, Dan
    Chaturvedi, Prasoon
    Niu, Deqiang
    Nacht, Mariana
    Petter, Russell C.
    Westlin, William
    Lin, Kevin
    Jaw-Tsai, Sarah
    Raponi, Mitch
    Van Dyke, Terry
    Etter, Jeff
    Weaver, Zoe
    Pao, William
    Singh, Juswinder
    Simmons, Andrew D.
    Harding, Thomas C.
    Allen, Andrew
    [J]. CANCER DISCOVERY, 2013, 3 (12) : 1404 - 1415
  • [10] Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
    Yu, Helena A.
    Tian, Shaozhou K.
    Drilon, Alexander E.
    Borsu, Laetitia
    Riely, Gregory J.
    Arcila, Maria E.
    Ladanyi, Marc
    [J]. JAMA ONCOLOGY, 2015, 1 (07) : 981 - 983
123